SEC Company Response from ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Oct 27, 2022
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: Oct. 27, 2022 · CIK: 0001281895 · Accession: 0001140361-22-038685
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267871
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attn: Christine Westbrook Registration Statement on Form S-4 (File No. 333-267871)
Re: Rocket Pharmaceuticals, Inc.
Dear Ms. Westbrook:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Rocket Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to Monday, October 31, 2022, at 9:00 a.m. Eastern Time, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Tevia K. Pollard at (617) 570-1084. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Tevia K. Pollard, by email at TPollard@goodwinlaw.com.
[Signature Page Follows]
Sincerely,
ROCKET PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
October 27, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christine Westbrook
Re:
Rocket Pharmaceuticals, Inc.
Registration Statement on Form S-4 (File No. 333-267871)
Dear Ms. Westbrook:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Rocket Pharmaceuticals, Inc. (the “Company”) hereby
requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to Monday, October 31, 2022, at 9:00 a.m. Eastern Time, or as soon thereafter as practicable. In making this acceleration
request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Tevia K.
Pollard at (617) 570-1084. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP,
Attention: Tevia K. Pollard, by email at TPollard@goodwinlaw.com.
[Signature Page Follows]
Sincerely,
ROCKET PHARMACEUTICALS, INC.
/s/ Gaurav Shah
Gaurav Shah
Chief Executive Officer
cc:
Martin Wilson, General Counsel, Rocket
Pharmaceuticals, Inc.
Sarah Ashfaq, Goodwin Procter LLP
William D. Collins, Goodwin Procter LLP
John T. Haggerty, Goodwin Procter LLP
Tevia K. Pollard, Goodwin Procter LLP